- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03155009
A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (ATALK)
February 7, 2020 updated by: Hoffmann-La Roche
An Open-Label, Multicenter, Single-Arm, Phase II Study to Assess the Efficacy and Safety of Alectinib in Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on Prior ALK Inhibitor Therapy
This study will evaluate the efficacy and safety of alectinib, in selected participants, with anaplastic lymphoma kinase-rearranged (ALK-rearranged) non-small cell lung cancer (NSCLC), after disease progression on prior treatment strategy with crizotinib, as only ALK inhibitor, and eventually chemotherapy treatment(s).
Study Overview
Study Type
Interventional
Enrollment (Actual)
44
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Angers, France, 49933
- CHU Angers
-
Besancon, France, 25030
- Hopital Jean Minjoz; Pneumologie
-
Brest, France, 29609
- Hopital Augustin Morvan; Oncologie Thoracique
-
Caen, France, 14076
- Centre Francois Baclesse; Comite 3
-
Creteil, France, 94010
- Centre Hospitalier Intercommunal; Service de Pneumologie
-
La Tronche, France, 38700
- Hôpital Nord Michallon; Pneumologie
-
Lille, France, 59000
- CHRU Lille Service de Pneumologie et Oncologie Thoracique
-
Marseille, France, 13915
- Hôpital Nord - AP-HM Marseille#
-
Mulhouse, France, 68070
- Hopital Emile Muller;Pneumologie
-
Paris, France, 75005
- Institut Curie
-
Paris, France, 75970
- Hopital Tenon;Pneumologie
-
Pessac, France, 33600
- CHU de Bordeaux
-
Rennes, France, 35033
- Hopital de Pontchaillou; Service de Pneumologie
-
Rouen, France, 76031
- CHU de Rouen - Hôpital Charles Nicolle
-
Toulouse cedex 9, France, 31100
- CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique
-
Vantoux, France, 57070
- Hopital Robert Schuman; Pneumologie
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants with histologically or cytologically confirmed locally advanced or metastatic NSCLC (Stage IIIB or IV accordingly to American Joint Committee on Cancer [AJCC] classification)
- Life expectancy of at least 12 weeks, in the opinion of the Investigator
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2
- Having contributive biopsy performed on fresh tissue (FFPE blocks required) taken after progression on previous therapy showing presence of anaplastic lymphoma kinase (ALK) rearrangement, assessed by immunohistochemistry (IHC) and confirmed by fluorescence in situ hybridization (FISH)
- Absence of resistance mechanism to alectinib assessed by the Biomarkers Board
- Disease progression, limited to central nervous system (CNS) without possibility of tissue biopsy
- Non-contributive molecular analyses (not enough tumor cells or deoxyribonucleic acid, [DNA] amount or failure of analyses for technical reasons): inclusion is at investigator discretion (decision made upon Biomarker Board recommendation)
- History of crizotinib exposure
- Washout period: if previous progression on crizotinib: 7 days from last intake of the drug
- If previous progression on chemotherapy: 28 days
- If previous radiation therapy: 15 days
- Participants must have recovered from treatment toxicities to ≤ Grade 1 or to their pretreatment levels (for participants who have developed interstitial lung disease [ILD], they must have fully recovered)
- Recovery from effects of any major surgery, or significant traumatic injury, at least 35 days before the first dose of alectinib
- Adequate hematologic function
- Adequate renal function
- For all females of childbearing potential, a negative pregnancy test must be obtained within three days before starting study drug
- For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of < 1% per year, during the treatment period and for at least 90 days after the last dose of study drug
- For men: agreement to remain abstinent or use a barrier method of contraception (e.g., condom) during the treatment period and for at least 90 days after the last dose of study drug and agreement to refrain from donating sperm during this same period
- Participant has national health insurance coverage
Exclusion Criteria:
- Prior therapy with other ALK inhibitors than crizotinib (including alectinib)
- Participants with symptomatic CNS metastases who are neurologically unstable or require increasing doses of steroids within one week prior to Day 0 to manage CNS symptoms
- Participants with progression limited to CNS and eligible to a focal treatment (surgery or stereotaxic radiotherapy)
- Administration of strong/ potent cytochrome P450 3A (CYP3A) inhibitors or inducers, or agents with potential QT prolonging effects within 14 days prior to first administration of study drug
- Liver disease
- Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the investigator, pose an unacceptable risk to the participant in this study
- Active or uncontrolled infectious diseases requiring treatment
- History of organ transplant
- Participants with baseline QTc > 470 ms or participants with symptomatic bradycardia
- Pregnant or lactating women
- History of hypersensitivity to any of the additives in the alectinib drug
- Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the participant before trial entry
- Serious, uncontrolled infections or current known infection with human immunodeficiency virus (HIV).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Alectinib
600 mg orally twice daily (BID) for up to 2 years
|
600 mg orally BID with food
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Up to 2 years
|
ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) assessed by the investigator using the Response Evaluation Criteria in Solid Tumors (RECIST), v.1.1.
CR is defined as disappearance of all target and non-target lesions and no new lesions, and all pathological lymph nodes must have decreased to <10 mm in short axis.
PR is defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Central Nervous System Objective Response Rate (C-ORR)
Time Frame: Up to 2 years
|
C-ORR is defined as the percentage of participants who attain a CR or PR of the baseline CNS metastases based on RECIST v.1.1.
CR is defined as disappearance of all target and non-target lesions and no new lesions, and all pathological lymph nodes must have decreased to <10 mm in short axis.
PR is defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions.
|
Up to 2 years
|
Progression-Free Survival (PFS)
Time Frame: Up to 2 years
|
PFS is defined as the time between first intake of alectinib and the first occurrence of disease progression, or death from any cause during the study, whichever occurs first.
Progressive disease (PD) based on RECIST v.1.1.
is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
The appearance of one or more new lesions is also considered progression.
|
Up to 2 years
|
Time to Progression (TTP)
Time Frame: Up to 2 years
|
TTP is defined as the time between first intake of alectinib and the first occurrence of disease progression.
PD based on RECIST v.1.1.
is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
The appearance of one or more new lesions is also considered progression.
|
Up to 2 years
|
Disease Control Rate (DCR)
Time Frame: Up to 2 years
|
DCR is defined as the percentage of participants who attain CR, PR, or stable disease (SD) for at least five weeks, based on RECIST v.1.1.
CR is defined as disappearance of all target and non-target lesions and no new lesions, and all pathological lymph nodes must have decreased to <10 mm in short axis.
PR is defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions.
SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum on study.
|
Up to 2 years
|
Duration of Response (DOR)
Time Frame: Up to 2 years
|
DOR is defined as the time from when response (CR or PR), based on RECIST v.1.1,
will be first documented to first documented disease progression or death (whichever occurs first).
CR is defined as disappearance of all target and non-target lesions and no new lesions, and all pathological lymph nodes must have decreased to <10 mm in short axis.
PR is defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions.
PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
The appearance of one or more new lesions is also considered progression.
|
Up to 2 years
|
Central Nervous System DOR (C-DOR)
Time Frame: Up to 2 years
|
C-DOR is defined as the time from the first observation of a CNS response of CR or PR based on RECIST V1.1 until first observation of CNS progression or death from any cause (whichever occurs first).
CR is defined as disappearance of all target and non-target lesions and no new lesions, and all pathological lymph nodes must have decreased to <10 mm in short axis.
PR is defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions.
PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
The appearance of one or more new lesions is also considered progression.
|
Up to 2 years
|
Overall Survival (OS)
Time Frame: Up to 2 years
|
OS is defined as the percentage of participants alive two years after the start of treatment.
|
Up to 2 years
|
Time to Central Nervous System (CNS) Progression
Time Frame: Up to 2 years
|
Time to central nervous system (CNS) progression is defined as the time from first drug intake to first documented occurrence of disease progression in the CNS.
PD based on RECIST v.1.1.
is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
The appearance of one or more new lesions is also considered progression.
|
Up to 2 years
|
Percentage of Participants with Adverse Events (AEs)
Time Frame: Up to 2 years
|
An adverse event is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.
Preexisting conditions that worsen during the study are reported as adverse events.
|
Up to 2 years
|
Health-Related Quality of Life (QoL), as Assessed by the QLQ-C30 Questionnaire
Time Frame: Up to 2 years
|
The QLQ-C30 Questionnaire is used to assess the quality of life of participants with cancer.
It includes five functional scales, three symptom scales, a global health status / QoL scale, and six single items.
These components range in score from 0 (low response level) to 100 (high response level).
|
Up to 2 years
|
Health-Related QoL, as Assessed by the LC13 Questionnaire
Time Frame: Up to 2 years
|
The LC13 Questionnaire includes 13 questions assessing lung cancer-associated symptoms (cough, hemoptysis, dyspnea and site-specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia), and pain medication.
This scale ranges in score from 0 (low response level) to 100 (high response level).
|
Up to 2 years
|
Health-Related QoL, as Assessed by the BN20 Questionnaire
Time Frame: Up to 2 years
|
The BN20 Questionnaire includes 20 items assessing future uncertainty, visual disorder, motor dysfunction, communication deficit and other disease symptoms, and treatment toxicities.
This scale ranges in score from 0 (low response level) to 100 (high response level).
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 10, 2017
Primary Completion (Actual)
September 26, 2019
Study Completion (Actual)
September 26, 2019
Study Registration Dates
First Submitted
May 11, 2017
First Submitted That Met QC Criteria
May 15, 2017
First Posted (Actual)
May 16, 2017
Study Record Updates
Last Update Posted (Actual)
February 10, 2020
Last Update Submitted That Met QC Criteria
February 7, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ML39349
- 2016-003924-22 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Non-Small-Cell Lung
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on Alectinib
-
Gruppo Oncologico Italiano di Ricerca ClinicaRecruiting
-
Aarhus University HospitalRoche Pharma AGEnrolling by invitationLung Cancer | ALK Gene Mutation | Resistance, Disease | MutationDenmark
-
Hoffmann-La RocheCompletedNon-Small Cell Lung CancerKorea, Republic of
-
ETOP IBCSG Partners FoundationHoffmann-La RocheTerminatedNon-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer RecurrentIreland, Spain, Belgium, Italy, Netherlands, Switzerland
-
Dana-Farber Cancer InstituteGenentech, Inc.TerminatedALK-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Thyroid CancerUnited States
-
University Medical Center GroningenRadboud University Medical Center; Maastricht University Medical Center; Erasmus... and other collaboratorsRecruitingCarcinoma, Non-Small-Cell Lung | Lung Cancer | Drug Monitoring | Anaplastic Lymphoma Kinase Gene Mutation | Anaplastic Lymphoma Kinase Gene TranslocationNetherlands, France
-
Hoffmann-La RocheActive, not recruitingNSCLCBelgium, Australia, China, Croatia, Finland, Turkey, Italy, Israel, Serbia, Austria, Romania, Peru, Lithuania, Colombia, Portugal, Czechia, Cuba, Russian Federation, Bulgaria, Vietnam, Uruguay, United Arab Emirates, Argentina, Chile, Pa...
-
PfizerCompletedNon-Small-Cell Lung CarcinomaUnited States
-
Hoffmann-La RocheCompletedHepatic ImpairmentCzechia, Slovakia
-
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...Not yet recruitingNon-small Cell Lung CancerUnited States